TALTZ (Eli Lilly Australia Pty Ltd)
Product name
TALTZ
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
159 working days (255)
Active ingredients
ixekizumab
Registration type
EOI
Indication
Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
TALTZ (solution for injection) is now also indicated for the treatment of active ankylosing spondylitis in adult patients.